A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

• Published in: AIDS (London) Vol. 24; no. 11; pp. 1781 - 1784
• Main Authors: TUNGSIRIPAT, Marisa, KITCH, Douglas, GLESBUY, Marshall J, GUPTA, Samir K, MELLORS, John W, MORAN, Laura, JONES, Lynne, ALSTON-SMITH, Beverly, ROONEY, James F, ABERG, Judith A
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 17-07-2010
• Subjects: Adenine - analogs & derivatives; Adenine - therapeutic use; Adult; Aged; Anti-HIV Agents - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiretroviral Therapy, Highly Active - adverse effects; Antiretroviral Therapy, Highly Active - methods; Antiviral agents; Biological and medical sciences; Cholesterol - blood; Dyslipidemias - blood; Dyslipidemias - drug therapy; Dyslipidemias - etiology; Epidemiologic Methods; Female; HIV Infections - blood; HIV Infections - complications; HIV Infections - drug therapy; HIV-1; Human immunodeficiency virus; Human viral diseases; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Infectious diseases; Male; Medical sciences; Middle Aged; Organophosphonates - therapeutic use; Pharmacology. Drug treatments; Pilot Projects; Tenofovir; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Young Adult; Immunopathology; Purine nucleotide; Antiretroviral agent; Acyclic nucleotide; RNA-directed DNA polymerase; Enzyme; Transferases; Enzyme inhibitor; Metabolic diseases; Lipids; AIDS; Organic phosphonate; Nucleotide analog; Immune deficiency; Infection; Tenofovir; Nucleotidyltransferases; Chemotherapy; Treatment; Reverse transcriptase inhibitor; Viral disease; Nucleoside analog; Antiviral; Dyslipemia
• ISSN: 0269-9370; 1473-5571
• DOI: 10.1097/qad.0b013e32833ad8b4

Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.